DNMT3L抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using DNMT3L mouse mAb (green) and negative control (red).    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using DNMT3L mouse mAb (green) and negative control (red).    

  
  

The DNMT3L antibody is a crucial tool in epigenetic research, targeting the DNA methyltransferase 3-like (DNMT3L) protein, a regulatory cofactor in the DNMT3 family. Unlike DNMT3A and DNMT3B, DNMT3L lacks catalytic activity but plays a vital role in de novo DNA methylation by stabilizing and enhancing the enzymatic function of DNMT3A/3B, particularly during gametogenesis and early embryogenesis. DNMT3L is essential for establishing genomic imprints and silencing retrotransposons in germ cells, making it critical for normal development and fertility.

Antibodies against DNMT3L are widely used to study its expression, localization, and interaction partners in tissues such as testes, ovaries, and embryonic stem cells. They enable detection via techniques like Western blotting, immunohistochemistry, and immunofluorescence, helping researchers investigate its role in epigenetic reprogramming and cellular differentiation. DNMT3L dysregulation has been linked to imprinting disorders (e.g., Prader-Willi syndrome), infertility, and cancer, where aberrant DNA methylation patterns drive oncogenesis. These antibodies also aid in exploring DNMT3L’s non-catalytic functions in chromatin remodeling and histone modification crosstalk. Validation often involves knockout models or siRNA knockdown to confirm specificity. As epigenetic therapies gain traction, DNMT3L antibodies remain pivotal for dissecting mechanisms underlying development, disease, and potential therapeutic targets.